BioSpace News Archive

Amgen (NASDAQ:AMGN) today announced the presentation of eight cardiovascular (CV) scientific research abstracts, including long-term and real-world evidence studies that add to the robust body of evidence demonstrating the efficacy and safety profile of Repatha® (evolocumab).

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), today announced positive results from a bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s Disease (AD).

Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based solutions for treating heart valves, announced a successful First-In-Human treatment of the mitral valve with the ShortCut™ Mitral device in Europe.

Lucid Hearing, LLC, a market leader and global provider of advanced hearing technology and audio solutions, commends the Food and Drug Administration (FDA) for its efforts to give Americans expanded access to hearing solutions.

A leading provider of Genomic services in the UK and Ireland, Source BioScience (“Source”), a part of SourceBio International plc, is now bringing decades of expertise and customer satisfaction in Genomic services to the USA.

PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present and host a fireside chat at the upcoming 2022 Wells Fargo healthcare conference.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of publications concluding that sotagliflozin’s differentiated dual SGLT1 and SGLT2 mechanism of action may have implications for cardiovascular disease.

CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company’s Amended and Restated 2017 Equity Incentive Plan and material to the employees’ acceptance of employment with the company.

Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the appointment of Cary J. Claiborne as President and Chief Executive Officer.